References
- Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273–81.
- André T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, . Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: A phase II study. Br J Cancer 2008;99:862–7.
- Gridelli C, Maione P, Rossi A, Guerriero C, Ferrara C, Del GF, . Chemotherapy of advanced NSCLC in special patient population. Ann Oncol 2006;17(Suppl 5):v72–8.
- Humphreys BD, Sharman JP, Henderson JM, Clark JW, Marks PW, Rennke HG, . Gemcitabine-associated thrombotic microangiopathy. Cancer 2004;100:2664–70.
- Amirlak I, Amirlak B. Haemolytic uraemic syndrome: An overview. Nephrology (Carlton) 2006;11:213–8.
- Skerka C, Jozsi M, Zipfel PF, Dragon-Durey MA, Fremeaux-Bacchi V. Autoantibodies in haemolytic uraemic syndrome (HUS). Thromb Haemost 2009;101:227–32.
- Gore EM, Jones BS, Marques MB. Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome? J Clin Apher 2009;24:209–14.
- Dahabreh I, Tsoutsos G, Tseligas D, Janinis D. Hemolytic uremic syndrome following the infusion of oxaliplatin: Case report. BMC Clin Pharmacol 2006;6:5.
- Bautista MA, Stevens WT, Chen CS, Curtis BR, Aster RH, Hsueh CT. Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: Two case reports and a review of the literature. J Hematol Oncol 2010;3:12.
- Faivre S, Raymond E, Woynarowski JM, Cvitkovic E. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999;44:117–23.